Cargando…

The utility of molecular diagnostics to predict recurrence of head and neck carcinoma

BACKGROUND: Locoregional recurrence is the major cause of treatment failure after surgery for oral squamous cell carcinoma. Molecular diagnostics have the potential to improve on clinicopathological parameters to predict this recurrence and plan adjuvant treatment. The test most frequently applied i...

Descripción completa

Detalles Bibliográficos
Autores principales: Pena Murillo, C, Huang, X, Hills, A, McGurk, M, Lyons, A, Jeannon, J-P, Odell, E, Brown, A, Lavery, K, Barrett, W, Sherriff, M, Brakenhoff, R, Partridge, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461148/
https://www.ncbi.nlm.nih.gov/pubmed/22918395
http://dx.doi.org/10.1038/bjc.2012.213
_version_ 1782245043243843584
author Pena Murillo, C
Huang, X
Hills, A
McGurk, M
Lyons, A
Jeannon, J-P
Odell, E
Brown, A
Lavery, K
Barrett, W
Sherriff, M
Brakenhoff, R
Partridge, M
author_facet Pena Murillo, C
Huang, X
Hills, A
McGurk, M
Lyons, A
Jeannon, J-P
Odell, E
Brown, A
Lavery, K
Barrett, W
Sherriff, M
Brakenhoff, R
Partridge, M
author_sort Pena Murillo, C
collection PubMed
description BACKGROUND: Locoregional recurrence is the major cause of treatment failure after surgery for oral squamous cell carcinoma. Molecular diagnostics have the potential to improve on clinicopathological parameters to predict this recurrence and plan adjuvant treatment. The test most frequently applied is based on detecting TP53 mutations, but alternative methodology is required for cases that harbour the wild-type gene. METHODS: One hundred and two cases with tumour-adjacent margins, considered to be clear margins by microscopy, were examined using carefully optimised molecular diagnostics based on detection of the TP53 and Ly-6D markers. The markers were also combined to provide a dual approach. RESULTS: The dual molecular diagnostic identified cases with a significant increase in the probablility of developing locoregional recurrence when tumour-adjacent positive and clear margins were compared (P=0.0001). These tests were most useful when the clearance at the resection margins was 5 mm or less. The TP53-based diagnostic was a better predictor of locoregional recurrence than established clinicopathological parameters. CONCLUSION: The optimised TP53-based diagnostic rapidly identifies an important subgroup of cases with close margins that will benefit from new treatment modalities to reduce the risk of recurrence.
format Online
Article
Text
id pubmed-3461148
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-34611482013-09-25 The utility of molecular diagnostics to predict recurrence of head and neck carcinoma Pena Murillo, C Huang, X Hills, A McGurk, M Lyons, A Jeannon, J-P Odell, E Brown, A Lavery, K Barrett, W Sherriff, M Brakenhoff, R Partridge, M Br J Cancer Molecular Diagnostics BACKGROUND: Locoregional recurrence is the major cause of treatment failure after surgery for oral squamous cell carcinoma. Molecular diagnostics have the potential to improve on clinicopathological parameters to predict this recurrence and plan adjuvant treatment. The test most frequently applied is based on detecting TP53 mutations, but alternative methodology is required for cases that harbour the wild-type gene. METHODS: One hundred and two cases with tumour-adjacent margins, considered to be clear margins by microscopy, were examined using carefully optimised molecular diagnostics based on detection of the TP53 and Ly-6D markers. The markers were also combined to provide a dual approach. RESULTS: The dual molecular diagnostic identified cases with a significant increase in the probablility of developing locoregional recurrence when tumour-adjacent positive and clear margins were compared (P=0.0001). These tests were most useful when the clearance at the resection margins was 5 mm or less. The TP53-based diagnostic was a better predictor of locoregional recurrence than established clinicopathological parameters. CONCLUSION: The optimised TP53-based diagnostic rapidly identifies an important subgroup of cases with close margins that will benefit from new treatment modalities to reduce the risk of recurrence. Nature Publishing Group 2012-09-25 2012-08-23 /pmc/articles/PMC3461148/ /pubmed/22918395 http://dx.doi.org/10.1038/bjc.2012.213 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Pena Murillo, C
Huang, X
Hills, A
McGurk, M
Lyons, A
Jeannon, J-P
Odell, E
Brown, A
Lavery, K
Barrett, W
Sherriff, M
Brakenhoff, R
Partridge, M
The utility of molecular diagnostics to predict recurrence of head and neck carcinoma
title The utility of molecular diagnostics to predict recurrence of head and neck carcinoma
title_full The utility of molecular diagnostics to predict recurrence of head and neck carcinoma
title_fullStr The utility of molecular diagnostics to predict recurrence of head and neck carcinoma
title_full_unstemmed The utility of molecular diagnostics to predict recurrence of head and neck carcinoma
title_short The utility of molecular diagnostics to predict recurrence of head and neck carcinoma
title_sort utility of molecular diagnostics to predict recurrence of head and neck carcinoma
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461148/
https://www.ncbi.nlm.nih.gov/pubmed/22918395
http://dx.doi.org/10.1038/bjc.2012.213
work_keys_str_mv AT penamurilloc theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT huangx theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT hillsa theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT mcgurkm theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT lyonsa theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT jeannonjp theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT odelle theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT browna theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT laveryk theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT barrettw theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT sherriffm theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT brakenhoffr theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT partridgem theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT penamurilloc utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT huangx utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT hillsa utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT mcgurkm utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT lyonsa utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT jeannonjp utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT odelle utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT browna utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT laveryk utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT barrettw utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT sherriffm utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT brakenhoffr utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma
AT partridgem utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma